TABLE 3.
Outcomes for participants to doxophylline group and non‐doxophylline group, clinical phenotypes, per‐protocol population.
| Primary outcomes | Neutrophilic | Eosinophilic | Mixed granulocytic | |||
|---|---|---|---|---|---|---|
| Doxophylline group | Non‐doxophylline group | Doxophylline group | Non‐doxophylline group | Doxophylline group | Non‐doxophylline group | |
| Number of severe exacerbations (n, %) | ||||||
| 1 month after discharge | 3 (3.9%) | 3 (3.9%) | 0 (0.0%) | 0 (0.0%) | 2 (3.8%) | 3 (5.8%) |
| Incidence rate ratio (95% CI) | 1.3 (0.3–6.0) | ‐ | 1.1 (0.2–5.8) | |||
| P value | 0.529 | ‐ | 0.941 | |||
| 3 months after discharge | 5 (6.6%) | 17 (22.4%) a | 5 (18.5%) | 1 (3.7%) | 7 (13.5%) | 6 (11.5%) |
| Incidence rate ratio (95% CI) | 0.4 (0.2–0.9) | 4.00 (0.54–29.81) | 1.9 (0.7–4.8) | |||
| P value | 0.024 | 0.182 | 0.188 | |||
| 6 months after discharge | 3 (3.9%) | 13 (17.1%) a | 0 (0.0%) | 4 (14.8%) a | 3 (5.8%) | 6 (11.5%) |
| Incidence rate ratio (95% CI) | 0.3 (0.1–0.9) | 1.5 (1.0–2.2) | 0.8 (0.2–2.8) | |||
| P value | 0.045 | 0.028 | 0.728 | |||
a
There was a clinically significant difference between DG and NDG.